RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptimmune Therapeutics Stock

Adaptimmune Therapeutics ROCE 2024

Adaptimmune Therapeutics ROCE

-3.31

Ticker

ADAP

ISIN

US00653A1079

WKN

A14SUX

In 2024, Adaptimmune Therapeutics's return on capital employed (ROCE) was -3.31, a 67.56% increase from the -1.97 ROCE in the previous year.

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Adaptimmune Therapeutics's Return on Capital Employed (ROCE)

Adaptimmune Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Adaptimmune Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Adaptimmune Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Adaptimmune Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Adaptimmune Therapeutics stock

What is the ROCE (Return on Capital Employed) of Adaptimmune Therapeutics this year?

The ROCE of Adaptimmune Therapeutics is -3.31 undefined this year.

How has the ROCE (Return on Capital Employed) of Adaptimmune Therapeutics developed compared to the previous year?

The ROCE of Adaptimmune Therapeutics has increased by 67.56% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Adaptimmune Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Adaptimmune Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Adaptimmune Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Adaptimmune Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Adaptimmune Therapeutics impact the company?

An increase in the ROCE of Adaptimmune Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Adaptimmune Therapeutics affect the company?

A decrease in ROCE of Adaptimmune Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Adaptimmune Therapeutics?

Some factors that can affect Adaptimmune Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Adaptimmune Therapeutics so important for investors?

The ROCE of Adaptimmune Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Adaptimmune Therapeutics take to improve the ROCE?

To improve the ROCE, Adaptimmune Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Adaptimmune Therapeutics in the year 2023?

In the year 2023, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adaptimmune Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adaptimmune Therapeutics

Our stock analysis for Adaptimmune Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptimmune Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.